Leukemia | Norton Healthcare

Indication: Leukemia

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Loxo Oncology

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.